AbbVie Inc. (NYSE:ABBV) Holdings Lifted by TFG Advisers LLC

TFG Advisers LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 0.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,830 shares of the company’s stock after acquiring an additional 111 shares during the quarter. AbbVie accounts for about 1.3% of TFG Advisers LLC’s portfolio, making the stock its 13th biggest holding. TFG Advisers LLC’s holdings in AbbVie were worth $3,702,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ABBV. Groupama Asset Managment boosted its position in shares of AbbVie by 40.3% in the 3rd quarter. Groupama Asset Managment now owns 135,749 shares of the company’s stock valued at $27,000 after purchasing an additional 38,974 shares during the period. RPg Family Wealth Advisory LLC acquired a new position in shares of AbbVie in the third quarter worth about $28,000. Fiduciary Advisors Inc. purchased a new position in shares of AbbVie in the fourth quarter worth approximately $29,000. Retirement Wealth Solutions LLC acquired a new stake in shares of AbbVie during the fourth quarter valued at approximately $35,000. Finally, Mizuho Securities Co. Ltd. lifted its position in shares of AbbVie by 100.0% in the 3rd quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company’s stock valued at $39,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.2 %

NYSE:ABBV opened at $190.67 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The company’s 50 day moving average is $177.38 and its 200-day moving average is $185.48. The firm has a market cap of $336.94 billion, a price-to-earnings ratio of 79.45, a P/E/G ratio of 1.84 and a beta of 0.58. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $207.32.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter last year, the business posted $2.79 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.26 EPS for the current year.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ABBV shares. Raymond James reissued an “outperform” rating and set a $220.00 target price (up from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Piper Sandler increased their price objective on AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Leerink Partnrs raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Piper Sandler Companies reissued an “overweight” rating and issued a $220.00 price target on shares of AbbVie in a research report on Tuesday, December 17th. Finally, Truist Financial boosted their price objective on shares of AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.